These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 7826903

  • 21. Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs.
    Aglietta M, Monzeglio C, Pasquino P, Carnino F, Stern AC, Gavosto F.
    Cancer; 1993 Nov 15; 72(10):2970-3. PubMed ID: 8221563
    [Abstract] [Full Text] [Related]

  • 22. Early suppressive effects of chemotherapy and cytokine treatment on committed versus primitive haemopoietic progenitors in patient bone marrow.
    Schwartz GN, Hakim F, Zujewski J, Szabo JM, Cepada R, Riseberg D, Warren MK, Mackall CL, Setzer A, Noone M, Cowan KH, O'Shaughnessy J, Gress RE.
    Br J Haematol; 1996 Mar 15; 92(3):537-47. PubMed ID: 8616014
    [Abstract] [Full Text] [Related]

  • 23. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE, Anderson SJ, Brown A, Scholnik AP, Desai AM, Kardinal CG, Lembersky BC, Mamounas EP.
    Clin Breast Cancer; 2002 Dec 15; 3(5):333-40. PubMed ID: 12533263
    [Abstract] [Full Text] [Related]

  • 24. Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients.
    Honkoop AH, Hoekman K, Wagstaff J, Boven E, van Groeningen CJ, Giaccone G, Vermorken JB, Pinedo HM.
    Ann Oncol; 1996 Jan 15; 7(1):35-9. PubMed ID: 9081389
    [Abstract] [Full Text] [Related]

  • 25. Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy Oncology Group.
    Colucci G, Giotta F, Gebbia V, Riccardi F, Pezzella G, Durini E, Caruso M, Romito S, Gebbia N.
    Anticancer Drugs; 1997 Mar 15; 8(3):257-64. PubMed ID: 9095330
    [Abstract] [Full Text] [Related]

  • 26. Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer.
    Budd GT, Atiba J, Silver RT, Palmer G, Armstrong S, Otto K, Presant C.
    J Cancer Res Clin Oncol; 1999 Mar 15; 125(8-9):500-4. PubMed ID: 10480343
    [Abstract] [Full Text] [Related]

  • 27. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer.
    Patrone F, Ballestrero A, Ferrando F, Brema F, Moraglio L, Valbonesi M, Basta P, Ghio R, Gobbi M, Sessarego M.
    J Clin Oncol; 1995 Apr 15; 13(4):840-6. PubMed ID: 7707109
    [Abstract] [Full Text] [Related]

  • 28. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
    Lichtman SM, Ratain MJ, Van Echo DA, Rosner G, Egorin MJ, Budman DR, Vogelzang NJ, Norton L, Schilsky RL.
    J Natl Cancer Inst; 1993 Aug 18; 85(16):1319-26. PubMed ID: 8340944
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H, Mulder NH, Willemse PH, van der Graaf WT, Sleijfer DT, Zijlstra JG, Elias M, Sibinga CT, Vellenga E, de Vries EG.
    Anticancer Res; 1995 Aug 18; 15(6B):2851-6. PubMed ID: 8669878
    [Abstract] [Full Text] [Related]

  • 34. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM, Cantin J, Chang J, Guevin R, Patel R, Tkaczuk K, Vodvarka P, Lindsay MA, Reese D, Riva A, Mackey J.
    Clin Breast Cancer; 2002 Oct 18; 3(4):268-75. PubMed ID: 12425755
    [Abstract] [Full Text] [Related]

  • 35. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial.
    Kritz A, Crown JP, Motzer RJ, Reich LM, Heller G, Moore MP, Hamilton N, Yao TJ, Heelan RT, Schneider JG.
    Cancer; 1993 Apr 15; 71(8):2515-21. PubMed ID: 8095854
    [Abstract] [Full Text] [Related]

  • 36. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
    Lamar RE, Greco FA, Johnson DH, Murphy PB, Hainsworth JD.
    Cancer; 1994 Apr 01; 73(7):1842-8. PubMed ID: 8137208
    [Abstract] [Full Text] [Related]

  • 37. Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.
    Sparano JA, Negassa A, Lansigan E, Locke R, De Silva CR, Wiernik PH.
    Med Oncol; 2005 Apr 01; 22(3):257-67. PubMed ID: 16110137
    [Abstract] [Full Text] [Related]

  • 38. An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer.
    Piccart MJ, Bruning P, Wildiers J, Awada A, Schornagel JH, Thomas J, Tomiak E, Bartholomeus S, Witteveen PO, Paridaens R.
    Ann Oncol; 1995 Sep 01; 6(7):673-7. PubMed ID: 8664188
    [Abstract] [Full Text] [Related]

  • 39. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer.
    Baldini E, Gardin G, Giannessi PG, Evangelista G, Roncella M, Prochilo T, Collecchi P, Rosso R, Lionetto R, Bruzzi P, Mosca F, Conte PF.
    Ann Oncol; 2003 Feb 01; 14(2):227-32. PubMed ID: 12562649
    [Abstract] [Full Text] [Related]

  • 40. A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.
    Shapiro JD, Harold N, Takimoto C, Hamilton JM, Vaughn D, Chen A, Steinberg SM, Liewehr D, Allegra C, Monahan B, Lash A, Grollman F, Flemming D, Behan K, Johnston PG, Haller D, Quinn M, Morrison G, Grem JL.
    Clin Cancer Res; 1999 Sep 01; 5(9):2399-408. PubMed ID: 10499610
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.